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2472Net Clinical Beneﬁt of Antithrombotic Therapy
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Chronic Kidney Disease
A Nationwide Observational Cohort StudyABSTRACTan
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MaBACKGROUND The balance between stroke reduction and increased bleeding associated with antithrombotic therapy
among patients with atrial ﬁbrillation (AF) and chronic kidney disease (CKD) is controversial.
OBJECTIVES This study assessed the risk associated with CKD in individual CHA2DS2-VASc (Congestive heart failure;
Hypertension; Age $75 years; Diabetes mellitus; previous Stroke, transient ischemic attack, or thromboembolism;
Vascular disease; Age 65 to 74 years; Sex category) strata and the net clinical beneﬁt of warfarin in patients with AF and
CKD in a nationwide cohort.
METHODS By individual-level linkage of nationwide Danish registries, we identiﬁed all patients discharged with non-
valvular AF from 1997 to 2011. The stroke risk associated with non-end-stage CKD and end-stage CKD (e.g., patients on
renal replacement therapy [RRT]) was estimated using Cox regression analyses. The net clinical beneﬁt of warfarin was
assessed using 4 endpoints: a composite endpoint of death/hospitalization from stroke/bleeding; a composite endpoint
of fatal stroke/fatal bleeding; cardiovascular death; and all-cause death.
RESULTS From nonvalvular AF patients (n ¼ 154,259), we identiﬁed 11,128 patients (7.2%) with non-end-stage CKD
and 1,728 (1.1%) receiving RRT. In all CHA2DS2-VASc risk groups, RRT was independently associated with a higher risk of
stroke/thromboembolism, from a 5.5-fold higher risk in patients with CHA2DS2-VASc score ¼ 0 to a 1.6-fold higher risk in
patients with CHA2DS2-VASc score $2. In patients receiving RRT with CHA2DS2-VASc score $2, warfarin was associated
with lower risk of all-cause death (hazard ratio [HR]: 0.85, 95% conﬁdence interval [CI]: 0.72 to 0.99). In non-end-stage
CKD patients with CHA2DS2-VASc score $2, warfarin was associated with a lower risk of a composite outcome of fatal
stroke/fatal bleeding (HR: 0.71, 95% CI: 0.57 to 0.88), a lower risk of cardiovascular death (HR: 0.80, 95% CI: 0.74
to 0.88), and a lower risk of all-cause death (HR: 0.64, 95% CI: 0.60 to 0.69).
CONCLUSIONS CKD is associated with a higher risk of stroke/thromboembolism across stroke risk strata in AF patients.
High-risk CKD patients (CHA2DS2-VASc $2) with AF beneﬁt from warfarin treatment for stroke prevention. (J Am Coll
Cardiol 2014;64:2471–82) © 2014 by the American College of Cardiology Foundation.T he optimal management of thromboprophy-laxis in patients with atrial ﬁbrillation (AF)and chronic kidney disease (CKD) is com-
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
CI = conﬁdence interval
CKD = chronic kidney disease
HR = hazard ratio
ICD = International
Classiﬁcation of Diseases
IQR = interquartile range
RRT = renal
replacement therapy
TE = thromboembolism
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2473risks of these important endpoints in individual
patients.
The published evidence for oral anticoagulation in
patients with AF shows that the use of adjusted dose
warfarin, compared with placebo, results in a 64%
reduction in stroke and, compared with placebo or
aspirin, a 26% reduction in all-cause mortality (5).
However, patients with a creatinine clearance of
<30 ml/min have been excluded from clinical trials
(6). Thus, antithrombotic treatment in patients with
CKD stages 4 to 5 and AF has hitherto been on the
basis of a number of small observational studies and a
few registry-based cohorts (7–12).SEE PAGE 2483We have previously shown that in AF patients
with CKD, warfarin treatment was associated with a
decreased risk of stroke/TE, as well as an increased risk of
bleeding (11). The present study investigated the net
clinical beneﬁt of antithrombotic therapy in patients with
bothAFandCKD (e.g., balancing efﬁcacy and safety of the
treatment). During recent years, there has been growing
attention to thequestionwhetherCKDshouldbe included
in stroke risk stratiﬁcation models (13–16), and validation
of stroke stratiﬁcation models should ideally be per-
formed in non-anti-coagulated real-world cohorts. For
this reason, the risk of stroke/TE associatedwith CKDwas
determined inpatientsnot receivingwarfarin, and thenet
clinical beneﬁt of warfarin was determined in individual
stroke risk strata, as determined by the CHA2DS2-VASc
(Congestive heart failure; Hypertension; Age $75 years;
Diabetes mellitus; previous Stroke, transient ischemic
attack, or thromboembolism; Vascular disease; Age 65 to
74 years; Sex category) score. First, we hypothesized that
CKDwouldbe independently associatedwithahigher risk
of stroke/TE inall stroke risk strataofnon-anti-coagulated
patients with AF. Second, we tested the hypothesis that
the beneﬁts of warfarin would outweigh its risks in AF
patients with CKD and a high risk of stroke/TE.
METHODS
In Denmark, linkage of data from nationwide regis-
tries on an individual level is possible using the
unique, permanent, and personal registration num-
ber provided to all Danish citizens. All Danish hos-
pital admissions since 1978 are registered in the
National Patient Registry with diagnoses coded ac-
cording to the International Classiﬁcation of Dis-
eases (ICD) system (17,18). Since 1996, invasive
therapeutic procedures have been coded according
to the Nordic Medical Statistics Committees Classi-
ﬁcation of Surgical Procedures. All prescriptions
dispensed from Danish pharmacies are registered in
the Danish National Prescription registry withinformation on drug strength, quantity, and
anatomical therapeutic chemical code
(19,20). Accurate data on all Danish patients
actively treated for end-stage CKD with RRT
are registered in the Danish Nephrology
Registry (21). The civil registration system
holds information on vital status for every
citizen (22), and information on primary and
contributing causes of death are registered
in the National Cause of Death Registry (23).
Diagnoses, surgical procedures, and phar-
macotherapy used for deﬁning the popula-
tion, comorbidity, and outcomes are
presented in Online Table 1. Ethical approval is not
required for retrospective register-based studies in
Denmark. The Danish Data Protection Agency
approved the study.
STUDY POPULATION. We identiﬁed all patients dis-
charged from a Danish hospital with nonvalvular AF
(ICD-10 code I48 or ICD-8 code 4279) as either pri-
mary or secondary diagnosis in the 15-year study
period from January 1, 1997 to December 31, 2011.
Pharmacotherapy may have been changed or intensi-
ﬁed in relation to the index AF hospitalization; there-
fore, follow-up began 7 days after discharge. Patients
that experienced stroke/TE, a major bleeding, or
died in this 7-day “quarantine” period were excluded
(Figure 1).
CHRONIC KIDNEY DISEASE AND RENAL REPLACEMENT
THERAPY. Patients with non-end-stage CKD were
identiﬁed from the National Patient Registry using
the diagnosis codes presented in Online Table 1. This
deﬁnition of non-end-stage CKD has been used earlier
(11,24). To evaluate the general level of renal function
in patients diagnosed with non-end-stage CKD, a
sample of 110 non-end-stage CKD patients (approxi-
mately 1% of the total non-end-stage CKD population)
was studied; estimated glomerular ﬁltration rate was
calculated according to the Modiﬁcation of Diet in
Renal Disease equation, using the ﬁrst plasma creat-
inine value during hospitalization, sex, and age (25).
Of these, 9 patients (8.2%) were stage-1, 12 (10.9%)
were stage-2, 22 (20.0%) were stage-3, 40 (36.4%)
were stage-4, and 27 (24.5%) were stage-5 CKD. Pa-
tients on RRT (i.e., hemodialysis, peritoneal dialysis,
or living with a renal transplant) were identiﬁed from
the well-validated Danish Nephrology Registry
(11,24). CKD status was determined at baseline and
time-dependently throughout follow-up: 1) non-CKD
patients could change status to non-end-stage CKD
or RRT during follow-up; 2) patients with non-end-
stage CKD could change status to RRT; and 3) RRT
patients could not change renal status (Figure 1). We
FIGURE 1 Study Population
- 248 were discharged within 7 days
from study end
- 3,352 died within 7 days from 
discharge
- 1,824 had a thromboembolism or a major
bleeding within 7 days from discharge
- 13,919 were treated with other thrombocyte
inhibitors than acetylsalicylic acid
19,334 were excluded:
6,609 (4.4%)
Non-end-stage CKD
during follow-up
221 (4.9%)
RRT during follow-up
249 (3.8%)
RRT during follow-up
116 (1.8%)
RRT during follow-up
1,142 (0.7%)
RRT
148,598 (96.5%)
Did not have renal
 disease
4,519 (2.9%)
Non-end-stage CKD
173,593
Patients discharged with non-valvular 
atrial fibrillation (1997-2011)
Dark blue boxes indicate patients at baseline; light blue boxes indicate changes during follow-up. CKD ¼ chronic kidney disease; RRT ¼ renal
replacement therapy.
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1997 to 2010.
PHARMACOLOGICAL TREATMENT. Pharmacological
treatment for all drugs other than warfarin and aspirin
at baseline was determined by claimed prescriptions
from 180 days before discharge to 7 days thereafter.
Patients receiving antiplatelet drugs other than aspirin
(i.e., clopidogrel, prasugrel, or dipyridamole) were
excluded from the study population (Figure 1). Periods
in which each patient was treated with warfarin,
aspirin, or both drugs were determined throughout
follow-up by dividing the number of tablets dispensed
with the estimated daily dosage (26,27). Dabigatran
was only recently approved in Denmark (October 2010)
and is unlikely to be used in most CKD patients due toits renal excretion. Therefore, we did not include
dabigatran data in our study.
THE CHA2DS2-VASC AND HAS-BLED SCORES. The
risk of stroke/TE for all patients was assessed accord-
ing to the CHA2DS2-VASc score (28,29). The CHA2DS2-
VASc score is calculated by adding 1 point each for the
presence of heart failure, hypertension, diabetes,
vascular disease, age 65 to 74 years, and female sex,
and 2 points each for the presence of previous stroke/
TE and age $75 years (30). A score of 0 was considered
“low risk,” 1 was “intermediate risk,” and$2was “high
risk” of stroke/TE. The risk of bleeding for all patients
was assessed using the HAS-BLED (Hypertension,
Abnormal renal function, abnormal liver function,
Stroke, Bleeding, Labile international normalized
TABLE 1 Baseline Characteristics for Patients With AF According to
Renal Disease at Baseline
No Renal Disease
(N ¼ 148,598)
Non-End-Stage CKD
(n ¼ 4,519)
RRT
(n ¼ 1,142)
Age, yrs 73.57  13.06 76.80  11.11 66.77  12.03
Stroke/TE comorbidity
Congestive heart failure 26,982 (18.16) 1,658 (36.69) 222 (19.44)
Hypertension 63,856 (42.97) 2,480 (54.88) 608 (53.24)
Age $75 yrs 79,550 (53.53) 2,927 (64.77) 345 (30.21)
Diabetes mellitus 13,267 (8.93) 1,128 (24.96) 191 (16.73)
Stroke/TE previous 20,441 (13.76) 804 (17.79) 187 (16.37)
Vascular disease 24,786 (16.68) 1,465 (32.42) 376 (32.92)
Age 65 to 74 yrs 35,952 (24.19) 992 (21.95) 357 (31.26)
Sex category, female 71,773 (48.30) 1,900 (42.04) 400 (35.03)
Concomitant medication
Warfarin 35,127 (23.64) 635 (14.05) 186 (16.29)
Warfarin and aspirin 16,992 (11.43) 495 (10.95) 74 (6.48)
Aspirin 41,956 (28.23) 1,668 (36.91) 299 (26.18)
Adrenergic alpha-antagonist 1,955 (1.32) 152 (3.36) 60 (5.25)
Non-loop diuretic agents 51,658 (34.76) 1,838 (40.67) 94 (8.23)
Beta blockers 67,854 (45.66) 2,037 (45.08) 663 (58.06)
Calcium-channel blockers 40,534 (27.28) 1,541 (34.10) 549 (48.07)
RASi 49,556 (33.35) 2,090 (46.25) 496 (43.43)
Loop diuretic agents 56,618 (38.10) 3,029 (67.03) 705 (61.73)
Statins 22,765 (15.32) 1,073 (23.74) 273 (23.91)
Digoxin 64,647 (43.50) 1,752 (38.77) 344 (30.12)
Amiodarone 5,221 (3.51) 194 (4.29) 40 (3.50)
CHA2DS2-VASc
Low, score 0 12,404 (8.35) 100 (2.21) 53 (4.64)
Intermediate, score 1 18,571 (12.50) 283 (6.26) 191 (16.73)
High, score 2–9 117,623 (79.16) 4,136 (91.52) 898 (78.63)
Bleeding comorbidity
Age $65 yrs 115,502 (77.73) 3,919 (86.72) 702 (61.47)
Abnormal liver function 2,567 (1.73) 156 (3.45) 46 (4.03)
Stroke/TE previous 20,441 (13.76) 804 (17.79) 187 (16.37)
History of bleeding 11,347 (7.64) 770 (17.04) 200 (17.51)
Alcohol abuse 5,722 (3.85) 205 (4.54) 51 (4.47)
Use of NSAID 27,862 (18.75) 919 (20.34) 110 (9.63)
HAS-BLED
0 or 1 65,914 (44.36) 1,278 (28.28) 536 (46.94)
2 56,176 (37.80) 1,947 (43.08) 399 (34.94)
$3 26,508 (17.84) 1,294 (28.63) 207 (18.13)
Values are mean  SD or n (%).
AF ¼ atrial ﬁbrillation; CHA2DS2-VASc ¼ Congestive heart failure; Hypertension, Age $75 years, Diabetes
mellitus, previous Stroke, transient ischemic attack, or thromboembolism, Vascular disease, Age 65 to 74 years,
Sex category; CKD ¼ chronic kidney disease; HAS-BLED ¼ Hypertension, Abnormal renal function, abnormal liver
function, Stroke, Bleeding, Labile international normalized ratio, Elderly, Drug therapy, alcohol intake. NSAID ¼
nonsteroidal anti-inﬂammatory drug; RASi ¼ renin-angiotensin system inhibitors; RRT ¼ renal replacement
therapy; TE ¼ thromboembolism.
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(11,31). The HAS-BLED score is calculated by adding 1
point each for the presence of hypertension, abnormal
renal or liver function, previous stroke/TE, a history of
bleeding, labile international normalized ratio,
age $65 years, concomitant therapy with nonsteroidal
anti-inﬂammatory drugs, and excessive alcohol
intake. As CKDwas the object of the study and because
international normalized ratio data were not available,
these risk factors were not included in the score.
STUDY OUTCOMES. Study outcomes under investi-
gation were the following: 1) hospitalization/death
from stroke/TE (32) (i.e., peripheral arterial embo-
lism, ischemic stroke, and transient ischemic attack);
2) a composite outcome of death/hospitalization from
stroke/TE/bleeding (i.e., gastrointestinal, intracra-
nial, urinary tract, and airway bleeding); 3) a com-
posite of fatal stroke/fatal bleeding; 4) cardiovascular
death; or 5) death from any cause (23). Outcome 1 was
used to determine the risk of stroke/TE associated
with CKD. Outcomes 2 to 5 were used to determine
the net clinical beneﬁt of antithrombotic therapy in
patients with AF and CKD.
STATISTICAL ANALYSIS. Event rates of stroke/TE
according to CKD, warfarin treatment, and CHA2DS2-
VASc score were estimated time-dependently. The
risk of stroke/TE associated with non-end-stage CKD,
and RRT in patients that were not treated with
warfarin was estimated in Cox proportional-hazards
survival models. Separate analyses were conducted
for patients at low, intermediate, and high risk of
stroke/TE. First, the Cox regression models were
adjusted for risk factors included in the CHA2DS2-
VASc score and aspirin treatment. Second, the Cox
regression models were adjusted for all baseline
characteristics, with age included in the model as a
continuous covariate. We used the Wald test to test
for differences between the non-end-stage CKD group
and the RRT group in our model. The net clinical
beneﬁt of warfarin and aspirin treatment was esti-
mated in time-dependent Cox proportional hazards
survival models outcomes 2 to 5. Analyses were con-
ducted separately for patients with non-end-stage
CKD and RRT, respectively, and according to
CHA2DS2-VASc score, with adjustment for changes in
renal status and antithrombotic treatment during
follow-up. Themodels were adjusted for risk factors in
the CHA2DS2-VASc score and theHAS-BLED score, with
age included in the model as a continuous covariate.
Treatment is often discontinued in terminal pa-
tients, and they may therefore erroneously appear to
die during an untreated period. This could lead to
false estimates that would favor treatment over notreatment. For this reason, net clinical beneﬁt
analyses of “fatal only” outcomes were made, with
patients analyzed as being in treatment until 30 days
after treatment discontinuation. Sensitivity analyses
were later conducted for all outcomes with treatment
periods of 0, 30, and 90 days, respectively.
Further, sensitivity analyses on the net clinical
beneﬁt of warfarin and aspirin were conducted
with separate columns for hemodialysis patients,
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cipients, respectively.
A 2-sided p value of <0.05 was considered statis-
tically signiﬁcant. All analyses were performed with
SAS statistical software (version 9.2, SAS Institute
Inc., Cary, North Carolina) and R (version 2.15.2,
R Development Core Team).
RESULTS
STUDY POPULATION. We included 154,259 patients
with nonvalvular AF during the 15-year study period
and identiﬁed a total of 11,128 patients (7.2%)with non-
end-stage CKD and 1,728 (1.2%) receiving RRT. Of
these, 4,519 had non-end-stage CKD and 1,142 were
receiving RRT at inclusion (Table 1). During follow-up,
6,609 patients developed non-end-stage CKD and
586 initiated RRT. Of the 1,728 patients receiving
RRT, 1,245 (72.0%) were receiving hemodialysis, 435
(25.1%) were receiving peritoneal dialysis, and 48
(2.8%) were kidney transplant recipients. Overall,
non-end-stage CKD patients were older, had more
comorbidities, and received more pharmacological
treatment, whereas RRT patients weremore oftenmen
and hypertensive. All CKD patients were less likely to
receive warfarin treatment. Among patients who had
CKD and CHA2DS2-VASc score ¼ 0 at baseline (n ¼ 153),
compared with intermediate and high-risk CKD pa-
tients, there were more patients with Wegener gran-
ulomatosis, chronic glomerulonephritis, or autosomal
dominant polycystic kidney disease. Of the 19,045
patients with CHA2DS2-VASc score ¼ 1, 5,642 patients
(29.6%) had this score because of their female sex.
Non-CKD patients had a median follow-up of 1,179
(interquartile range [IQR]: 397 to 2,412) days and in
this period 19,877 patients (13.4%) experienced
stroke/TE. Non-end-stage CKD patients had a median
follow-up of 312 (IQR: 48 to 952) days and 1,087
(9.9%) experienced stroke/TE. RRT patients had a
median follow-up of 603 (IQR: 225 to 1,300) days and
227 (13.2%) had stroke/TE. A total of 322 patientsTABLE 2 Rates (95% CI; Number of Events) of Stroke and TE per 100
Warfarin Treatment, and CHA2DS2-VASc Score
CHA2DS2-VASc Score
No CKD
Not Receiving
Warfarin
(n ¼ 96,479*)
Receiving
Warfarin
(n ¼ 52,119*)
Not
W
(n ¼
0 0.8 (0.7–0.8; 446) 0.7 (0.6–0.9; 149) 2.1 (0
1 1.4 (1.4–1.5; 966) 1.0 (0.9–1.1; 358) 1.5 (0
$2 5.3 (5.2–5.4; 13,622) 2.9 (2.8–3.0; 4336) 7.2 (6
Time-dependent exposures: patients were able to change renal status and warfarin t
during follow-up.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.emigrated during the study period and were censored
on the date of emigration. Online Table 2 shows the
exact numbers of all events in our study. Online
Figure 1 shows cumulative incidence curves of car-
diovascular death according to CHA2DS2-VASc score
and CKD group.
RISK OF STROKE/TE. Table 2 displays rates of stroke/
TE according to CKD, warfarin treatment, and
CHA2DS2-VASc score. In patients with CHA2DS2-VASc
score ¼ 0 not treated with warfarin, the stroke/TE rate
per 100 person-years increased from 0.8 (95% conﬁ-
dence interval [CI]: 0.7 to 0.8) in patients without
CKD to 4.2 (95% CI: 1.5 to 6.9) in RRT patients. In
patients with CHA2DS2-VASc score $2 not treated
with warfarin, the stroke/TE rate was substantially
increased in both non-end-stage CKD and RRT pa-
tients when compared with AF patients without CKD.
Event rates of stroke/TE were generally lower in
patients treated with warfarin than in those patients
not treated with warfarin. When female patients
with CHA2DS2-VASc score ¼ 1 were reclassiﬁed as
CHA2DS2-VASc score ¼ 0, given that such patients are
“low risk,” the following event rates were obtained in
the non-anti-coagulated patients: non-end-stage CKD
patients as low risk had a stroke/TE rate of 1.6 per 100
person-years, compared with a stroke/TE rate of 1.8 in
non-end-stage CKD patients at intermediate risk, and
RRT patients at low risk had a stroke/TE rate of 3.1,
compared with a stroke/TE rate of 3.2 in RRT patients
at intermediate risk, respectively.
Table 3 shows the results from Cox proportional
hazards survival model, adjusted for CHA2DS2-VASc
score and aspirin treatment, and CHA2DS2-VASc score
and all baseline medication, respectively. Among AF
patients with CHA2DS2-VASc score ¼ 0, CKD was
associated with a higher risk of stroke/TE among both
non-end-stage CKD and RRT patients when compared
with patients without CKD. This association was not
found in non-end-stage CKD patients with CHA2DS2-
VASc score ¼ 1 (hazard ratio [HR]: 0.94, 95% CI: 0.60
to 1.48). CKD was independently associated with aPerson-Years In Patients With AF According to Renal Status,
Non-End-STAGE CKD RRT
Receiving
arfarin
3,389*)
Receiving
Warfarin
(n ¼ 1,130*)
Not Receiving
Warfarin
(n ¼ 882*)
Receiving
Warfarin
(n ¼ 260*)
.9–3.4; 11) 1.3 (0.0–3.7; 3) 4.2 (1.5–6.9; 9) 0
.9–2.2; 19) 1.8 (0.7–2.8; 11) 2.8 (1.6–4.1; 21) 3.3 (0.8–5.7; 7)
.7–7.7; 763) 5.8 (5.1–6.4; 280) 7.3 (6.2–8.5;156) 4.8 (3.2–6.4; 34)
reatment during follow-up. *Number of patients at baseline; this number changed
TABLE 3 HR (95% CI) of Stroke and TE in Patients With AF Not Receiving Warfarin
(n ¼ 100,750*)
Adjusted for Aspirin
Treatment and Risk Factors
Included in the CHA2DS2-VASc Score
Adjusted for Aspirin
Treatment and All
Baseline Characteristics†
All patients
Non-end-stage CKD 1.31 (1.22–1.41) 1.32 (1.23–1.42)
RRT 1.82 (1.58–2.12) 2.01 (1.74–2.33)
CHA2DS2-VASc score ¼ 0
Non-end-stage CKD 2.73 (1.50–4.97) 2.07 (1.13–3.79)
RRT 5.54 (2.86–10.73) 4.42 (2.26–8.61)
CHA2DS2-VASc score ¼ 1
Non-end-stage CKD 0.94 (0.60–1.48) 0.94 (0.60–1.49)
RRT 2.23 (1.44–3.45) 2.09 (1.33–3.29)
CHA2DS2-VASc score $2
Non-end-stage CKD 1.31 (1.22–1.41) 1.33 (1.23–1.43)
RRT 1.64 (1.40–1.93) 1.82 (1.55–2.14)
Reference was AF patients without CKD. Results from time-dependent Cox regression analyses: patients were
able to change renal status and antithrombotic treatment during follow-up. *Number of non-warfarin treated at
baseline; this number changed during follow-up. †Age was adjusted for as a continuous covariate.
HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
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2477higher risk of stroke/TE in high-risk patients
(CHA2DS2-VASc score $2): from a 1.3-fold higher risk
with non-end-stage CKD to a 1.6-fold higher risk with
RRT. There was a signiﬁcant difference between the
non-end-stage CKD group and the RRT group in pa-
tients with CHA2DS2-VASc score $1 (p value for
interaction <0.0001).
WARFARIN AND ASPIRIN TREATMENT. Results from
Cox regression analyses on net clinical beneﬁt are
shown in Figure 2. Among high-risk non-end-stage
CKD patients, warfarin was associated with a lower
risk of cardiovascular death (HR: 0.80, 95% CI: 0.74 to
0.88) and all-cause mortality (HR: 0.64, 95% CI: 0.60
to 0.69) than no antithrombotic treatment was.
Among low-/intermediate-risk non-end-stage CKD
patients, warfarin was associated with a signiﬁcantly
lower risk of all-cause mortality (HR: 0.62, 95% CI:
0.49 to 0.79) and a non-signiﬁcant trend toward lower
risk of cardiovascular death. Treatments with aspirin
and aspirin plus warfarin were associated with a
lower risk of all-cause mortality, but not with a lower
risk of any other outcome.
Among high-risk RRT patients, warfarin was asso-
ciated with a signiﬁcantly lower risk of all-cause
mortality (HR: 0.85, 95% CI: 0.72 to 0.99) and non-
signiﬁcant trends toward lower risks of cardiovascu-
lar death and of a composite of death/hospitalization
from stroke/TE/bleeding, respectively. Treatment
with aspirin or aspirin plus warfarin was not associ-
ated with a lower risk of any outcome among RRT
patients.
Online Figure 2 shows results from time-
dependent analyses on “fatal stroke/fatal bleeding.”
Among high-risk non-end-stage CKD patients, war-
farin was associated with a lower risk of a composite
outcome of fatal stroke/fatal bleeding (HR: 0.71,
95% CI: 0.57 to 0.88).
Analyses of associations between of antithrom-
botic treatment and all outcomes investigated in this
study were also performed for hemodialysis patients,
peritoneal dialysis patients, and renal transplant re-
cipients (Online Table 3). There was a signiﬁcant
interaction between the 2 dialysis modalities on
warfarin in low-risk patients (p ¼ 0.002) and on
aspirin in high-risk patients for the outcome of
stroke/TE/bleeding (p ¼ 0.041). There was a trend
toward fewer negative outcomes with warfarin
among high-risk hemodialysis patients than among
high-risk peritoneal dialysis patients. Excluding renal
transplanted patients from the RRT group did not
alter the direction of any of the results.
Online Table 4 shows net clinical beneﬁt analyses of
antithrombotic treatment in patients with AF and CKDwhen prolonging treatment periods in the analyses for
0, 30, and 90 days, respectively. Prolonging treatment
periods resulted in more conservative risk estimates
and wider conﬁdence intervals for all study outcomes
and all treatments investigated. Warfarin was associ-
ated with a lower risk of all-cause mortality in patients
with non-end-stage CKD after prolonging treatment
periods for both 30 and 90 days. After prolonging
treatment periods for 30 days, warfarin was still
signiﬁcantly associated with a lower risk of all-cause
mortality in patients with AF on RRT, but this associ-
ation was not found after prolonging treatment pe-
riods for 90 days. The study design and main results
are summarized in the Central Illustration.
DISCUSSION
This nationwide study investigated the risk of stroke/
TE and the net clinical beneﬁt of antithrombotic
treatment in patients with AF and CKD. First, RRT
patients in all stroke risk (CHA2DS2-VASc score)
strata had a higher HR of stroke/TE. Second, in RRT
patients with CHA2DS2-VASc score $2, warfarin was
associated with a signiﬁcant net clinical beneﬁt, as
warfarin was associated with a lower risk of all-cause
mortality, a nonsigniﬁcant trend toward lower risk of
cardiovascular death and a composite outcome of
death/hospitalization from stroke/TE/bleeding. Third,
non-end-stage CKD patients with CHA2DS2-VASc score
$2 or CHA2DS2-VASc ¼ 0 had higher HR of stroke/TE.
Fourth, treatment with warfarin in high-risk non-end-
stage CKD patients was associated with a signiﬁcant
net clinical beneﬁt, as it was associated with a lower
FIGURE 2 Net Clinical Beneﬁt of Antithrombotic Therapy in Patients With AF and CKD
All stroke or all bleeding
Intermediate/low risk
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Warfarin
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1.32 [0.74–2.37]
1.49 [0.88–2.52]
0.65 [0.15–2.73]
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Non-end-stage chronic kidney disease Renal replacement therapy 
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Results from time-dependent Cox regression analyses. Patients were able to change renal status and antithrombotic treatment during follow-
up. Analyses were adjusted for risk factors included in the CHA2DS2-VASc and HAS-BLED score with age as a continuous covariate. In the
analyses with “cardiovascular death” and “all-cause mortality” as the outcome, patients were considered in-treatment until 30 days after
treatment cessation. AF ¼ atrial ﬁbrillation; CHA2DS2-VASc ¼ Congestive heart failure, Hypertension, Age $75 years, Diabetes mellitus,
previous Stroke, transient ischemic attack, or thromboembolism, Vascular disease, Age 65 to 74 years, Sex category; CKD ¼ chronic kidney
disease; HAS-BLED ¼ Hypertension, Abnormal renal function, abnormal liver function, Stroke, Bleeding, Labile international normalized ratio,
Elderly, Drug therapy, alcohol intake. *Not all patients had chronic kidney disease at baseline.
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2478risk of the composite outcome of fatal stroke/fatal
bleeding, a lower risk of cardiovascular death, and a
lower risk of all-cause mortality, respectively.
Of note, CKD patients not treated with warfarin
with CHA2DS2-VASc ¼ 1 had lower rates of stroke/TE
than did CKD patients with CHA2DS2-VASc ¼ 0 in
our study. When we grouped female patients with
CHA2DS2-VASc score ¼ 1 together with CHA2DS2-VASc
score ¼ 0 (e.g., classifying these patients as “low risk”
in accordance with 2012 European Society of Cardi-
ology guidelines [30]), other CKD patients withCHA2DS2-VASc score ¼ 1 had higher rates of stroke/TE
than did CKD patients with CHA2DS2-VASc score ¼ 0.
It has recently been debated whether CKD should
be added as an extra risk point to the CHA2DS2-VASc
score (13–16). We found that RRT was independently
associated with a higher HR of stroke/TE in all stroke
risk strata of the CHA2DS2-VASc score, from a 5.5-fold
higher risk in low-risk patients to a 1.6-fold higher
risk in high-risk patients. Non-end-stage CKD was
independently associated with a higher HR of stroke/
TE in patients with CHA2DS2-VASc ¼ 0 or 2. Warfarin
CENTRAL ILLUSTRATION Net Clinical Beneﬁt of Antithrombotic Therapy in Patients With AF and CKD
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Bonde, A.N. et al. J Am Coll Cardiol. 2014; 64(23):2471–82.
(A) Study design: cross-linking Danish registries into a single database using the personal registration number. (B) Study results: chronic
kidney disease (CKD) was independently associated with a higher risk of stroke. (C) Study results: warfarin was associated with a net clinical
beneﬁt in high-risk atrial ﬁbrillation (AF) patients with chronic kidney disease. CHA2DS2-VASc¼ Congestive heart failure, Hypertension, Age$75
years, Diabetes mellitus, previous Stroke, transient ischemic attack, or thromboembolism, Vascular disease, Age 65 to 74 years, Sex category.
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2480was associated with a lower risk of all-cause mortality
in non-end-stage CKD patients with CHA2DS2-
VASc #1. In these latter low-/intermediate-risk CKD
patients, our results may therefore suggest a poten-
tial beneﬁt of warfarin.
One previous study found warfarin to be beneﬁcial
in AF patients with non-end-stage CKD compared to
no-treatment patients (33). Our study supports these
ﬁndings, considering that warfarin was found to be
associated with a net clinical beneﬁt among high-risk
non-end-stage CKD patients. Among patients with AF
receiving RRT, the value of warfarin has previously
been challenged, and routine anticoagulation for
primary stroke prevention has not been recom-
mended (34), given that these patients were excluded
from previous clinical trials. Some observational
studies have reported higher rates of stroke or
bleeding with warfarin among RRT patients (7,9,12),
whereas others did not ﬁnd this association (8,11,35),
and 1 study, like the present analysis, found a lower
risk of all-cause mortality with warfarin (10). Com-
pared with previous studies, our study perhaps has
greater clinical relevance and application, given the
large size and the fact that we accounted for different
stroke risk strata in our analyses. We found a net
clinical beneﬁt of warfarin in RRT patients with
CHA2DS2-VASc score $2. This association was still
signiﬁcant when prolonging treatment periods for 30
days but not when prolonging treatment periods for
90 days, indicating that some of the apparent positive
effect associated with warfarin may be caused by
treatment cessation in some of the terminal patients.
When compared with no antithrombotic treatment,
aspirin, which has previously been used for antith-
rombotic therapy among RRT patients who are
considered unsuitable for warfarin treatment, was
not associated with a net clinical beneﬁt in any
analysis. The relationship between reduced stroke/TE
and increased bleeding with antithrombotic therapy
might differ across the various RRT modalities. We
observed a trend toward fewer negative outcomes
with warfarin among high-risk hemodialysis patients
than among high-risk peritoneal dialysis patients, but
this difference was not seen on all-cause mortality.
STUDY STRENGTHS AND LIMITATIONS. This study is
limited by its observational cohort design and there-
fore residual confounding may still be present. Data
on renal function were not available for all patients,
and we were therefore unable to stratify the non-end-
stage CKD group into glomerular ﬁltration rate cate-
gories or to account for changes in renal function
during the study period. Patients emigrating during
the study period were lost to follow-up, and we hadno information on eventual health care contacts
outside of Denmark. Because diabetes, heart failure,
and hypertension were identiﬁed on the basis of ﬁlled
prescriptions, the frequency of these risk factors
might have been underestimated, and the number of
patients with low risk of stroke/TE might have been
overestimated, because an unknown number of pa-
tients may have been treated with diet and lifestyle
interventions alone. We were not able to control for
blood pressure per se due to the lack of data on blood
pressure measurements. The inclusion of only hos-
pitalized patients with AF increased the proportion of
patients at high risk of stroke/TE and death. We were
not able to distinguish between paroxysmal and
persistent AF. Because aspirin can be bought over the
counter in Denmark, we might have underestimated
the number of aspirin users. Because some dialysis
centers in Denmark have reported that they use
warfarin for patients without prescription, we might
have underestimated the number of RRT patients that
used warfarin. We did not have access to brain im-
aging data, and some of the strokes reported as
ischemic might have been hemorrhagic, although a
previous study (32) on the subject did not ﬁnd
this potential bias to be of major importance. The
strengths of our data are that the positive predictive
value of the AF diagnosis in our study is very high
(36), and the stroke diagnosis is well validated (32).
Information on all-cause mortality is accurate (23).
Our RRT information is also precise (21).
CONCLUSIONS
We have found that among AF patients, CKD was
associated with a higher risk of stroke/TE across
stroke risk (CHA2DS2-VASc) strata, most notably
among RRT patients. In RRT patients with CHA2DS2-
VASc score $2, warfarin was associated with a net
clinical beneﬁt, as it was associated with a lower risk
of all-cause mortality. In non-end-stage CKD patients
with CHA2DS2-VASc score $2, warfarin was associated
with a net clinical beneﬁt, as it was associated
with a lower risk of all-cause mortality, a lower risk
of cardiovascular death, and a lower risk of the
composite outcome of fatal stroke/fatal bleeding,
respectively. These observations provide guidance
for the optimal use of antithrombotic therapy in AF
patients with CKD.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Patients with AF who have severe CKD have been
excluded from most randomized trials involving anticoa-
gulation for stroke prevention, but warfarin is associated
with net clinical beneﬁt.
COMPETENCY IN PATIENT CARE: Warfarin therapy
is generally beneﬁcial for patients with AF and CKD
unless contraindicated for other reasons.
TRANSLATIONAL OUTLOOK: There is a need
for further studies, including randomized trials comparing
warfarin with dose-adjusted target-speciﬁc oral antico-
agulants, in patients with AF and CKD to assess safety and
efﬁcacy for prevention of thromboembolism in addition
to the impact of treatment on the progression of renal
disease.
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